2003
Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria.
Cashman J, Camp K, Fakharzadeh S, Fennessey P, Hines R, Mamer O, Mitchell S, Nguyen G, Schlenk D, Smith R, Tjoa S, Williams D, Yannicelli S. Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Current Drug Metabolism 2003, 4: 151-70. PMID: 12678693, DOI: 10.2174/1389200033489505.Peer-Reviewed Original ResearchConceptsMonooxygenase form 3Rare metabolic disorderFoul body odorPrimary genetic formsTreatment of individualsNutritional supportVitamin supplementationPlasma cholineTreatment strategiesClinical aspectsClinical basisDrug treatmentMetabolic disordersChildhood formUrinary trimethylamineBody secretionsAbnormal amountsGenetic formsDisease statesDietary sourcesTrimethylamine N-oxideTrimethylaminuriaVariant formDisordersBody odor
2002
GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO)
Krueger S, Williams D, Yueh M, Martin S, Hines R, Raucy J, Dolphin C, Shephard E, Phillips I. GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO). Drug Metabolism Reviews 2002, 34: 523-532. PMID: 12214664, DOI: 10.1081/dmr-120005653.Peer-Reviewed Original ResearchConceptsFlavin-Containing MonooxygenaseAdult human liverPercent of individualsPlethora of drugsTrimethylamine N-oxygenationDrug metabolismHuman liverGenetic polymorphismsHispanic descentPremature stop codonPolymorphic expressionLungPreliminary evidenceFunctional FMO2African descentXenobiotic toxicityMammalian flavinN-oxygenationFMO2TrimethylaminuriaEthylene thioureaPolymorphismAllelesPatientsExpression